Test Catalog

Test ID: HCVDR    
Hepatitis C Virus Genotypic Antiviral Drug Resistance, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Detection and identification of codon substitutions in the hepatitis C virus (HCV) NS3, NS5A, and NS5B genomic regions that confer resistance to current direct-acting antiviral (DAA) drugs used for treatment of chronic hepatitis C infection due to HCV genotype 1a, 1b, or 3 (any subtype)


Guiding initiation or change of antiviral drug combinations for the treatment of chronic HCV infection


This assay should not be used as a screening test for HCV infection.


This test should not be ordered for HCV infection due to genotype 2, 4, 5, or 6.


This assay uses next-generation sequencing to detect and identify hepatitis C virus (HCV) antiviral drug resistance in patients with chronic hepatitis C and those being considered for direct-acting antiviral (DAA) drug combination therapy.


This test can be used to predict the likelihood of a curative response to current FDA-approved DAA drug combinations used for treatment of chronic hepatitis C.

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Polymerase Chain Reaction followed by Next-Generation Sequencing (sequencing by synthesis method)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

HCV Genotypic Drug Resistance, S

Aliases Lists additional common names for a test, as an aid in searching

HCV DAA resistance
HCV genotype
HCV genotyping
HCV drug resistance
HCV resistance